JCAR017: Additional Phase I/II data

Data from 42 evaluable pediatric patients with relapsed or refractory CD19+ ALL in the open-label, U.S. Phase I/II PLAT-02 trial showed that JCAR017 led to a complete remission rate of 93%. The trial ...